Phase II Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer
Latest Information Update: 04 Feb 2026
At a glance
- Drugs Evofosfamide (Primary)
- Indications Chronic obstructive pulmonary disease; Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 28 Jan 2026 Planned End Date changed from 1 Apr 2029 to 27 May 2030.
- 28 Jan 2026 Planned primary completion date changed from 1 Apr 2027 to 27 May 2028.
- 28 Jan 2026 Planned initiation date changed from 1 Apr 2025 to 27 May 2026.